Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits
Language English Country Netherlands Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
15661572
DOI
10.1016/j.phrs.2004.08.005
PII: S1043-6618(04)00215-4
Knihovny.cz E-resources
- MeSH
- Daunorubicin toxicity MeSH
- Isoniazid analogs & derivatives pharmacology MeSH
- Cardiotonic Agents pharmacology MeSH
- Rabbits MeSH
- Myocardium metabolism pathology MeSH
- Pyridoxal analogs & derivatives pharmacology MeSH
- Heart Ventricles drug effects metabolism pathology MeSH
- Animals MeSH
- Check Tag
- Rabbits MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Daunorubicin MeSH
- Isoniazid MeSH
- Cardiotonic Agents MeSH
- pyridoxal isonicotinoyl hydrazone MeSH Browser
- Pyridoxal MeSH
Risk of cardiotoxicity is the most serious drawback of the clinical usefulness of anthracycline antineoplastic antibiotics, which however, remain among the most powerful and widely employed anticancer drugs. In this study we have used daunorubicin-induced cardiomyopathy in rabbits as a model to investigate possible cardioprotective effects of pyridoxal isonicotinoyl hydrazone (PIH)-a principal representative of a novel group of aroylhydrazone iron chelators. Three groups of animals were used: a control group (n=11; i.v. saline), daunorubicin-treated animals (n=11; 3mg/kg, i.v.), and animals pretreated with PIH (n=9, 25 mg/kg, i.p.) 60 min before daunorubicin administration. All substances were administered once weekly for 10 weeks. Repeated administration of daunorubicin caused premature death in four animals and induced conspicuous histopathological changes in the myocardium, progressive and significant impairment of systolic heart function (a decrease in left ventricular dP/dt(max), ejection fraction, an increase in the pre-ejection period/left ventricular ejection time index), and a gradual increase in cardiac troponin T plasma concentrations. On the contrary, all the PIH-treated animals have survived all daunorubicin applications. Furthermore, in this group, the daunorubicin-induced cardiac changes were in most functional, biochemical as well as morphological parameters less pronounced than in the group receiving daunorubicin alone. Hence, PIH and other aroylhydrazones merit further investigation as potentially protective agents against anthracycline-induced cardiotoxicity.
References provided by Crossref.org
Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin